Astrana Health, INC

Astrana Health announced its Accountable Care Organizations generated $120.4 million in gross shared savings for the 2024 performance year, with all eight ACOs achieving net shared savings.

Astrana Health, Inc. reported the retirement of its Chief Accounting Officer, Glenn Sobotka, effective August 7, 2026, with John Vong appointed as his successor.

Astrana Health stockholders approved the amended 2024 Equity Incentive Plan and re-elected nine directors at the 2026 Annual Meeting.

Astrana Health, Inc. reports the resignation of its Chief Medical Officer, Dinesh Kumar, M.D., effective June 1, 2026.

Astrana Health, Inc. has released an updated corporate presentation for use in investor meetings and conferences.

Astrana Health, Inc. has completed its $674.9 million acquisition of Prospect Health Plan and Alta Newport Hospital, significantly increasing its pro forma annual revenue to over $3.8 billion.

Astrana Health, Inc. (ASTH) announced a significant increase in revenue and net income for the first quarter of 2026, driven by strategic acquisitions and organic growth.

Astrana Health, Inc. reported a significant 100% increase in total revenue for Q3 2025, reaching $956.0 million, primarily driven by the acquisition of Prospect Medical Holdings, Inc., despite a substantial drop in net income.

Astrana Health reports significant revenue growth driven by recent acquisitions, despite a decline in net income and operating profit for the second quarter and first half of 2025.

Astrana Health's Q1 2025 revenue increased by 53% year-over-year, driven by capitation growth, while net income saw a decrease.

Astrana Health's third quarter 2024 results show a significant 37% increase in revenue, driven primarily by capitation growth and recent acquisitions.

Astrana Health, Inc. saw a significant increase in revenue during the second quarter of 2024, primarily driven by recent strategic acquisitions and growth in capitation revenue.

Astrana Health's 2025 annual report highlights significant revenue and Adjusted EBITDA growth driven by strategic acquisitions, despite a decline in net income and an identified material weakness in internal controls.

Astrana Health's 2024 10-K filing highlights strategic acquisitions, financial performance, and future outlook in the value-based healthcare sector.

Astrana Health, Inc. details its common and preferred stock structure, voting rights, dividend policies, and anti-takeover provisions in a recent SEC filing.

Director David Schmidt was granted 4,525 restricted shares of Astrana Health, Inc. common stock.

Director Matthew Mazdyasni was granted 4,525 restricted shares of Astrana Health, Inc. common stock.

Director Mitchell W. Kitayama was granted 4,991 restricted shares of Astrana Health common stock.

Astrana Health, Inc. director Linda Dong was granted 4,525 restricted shares of common stock vesting in June 2027.

Astrana Health Director Weili Dai acquired 4,525 restricted shares of common stock, vesting by June 2027, under the company's 2024 Equity Incentive Plan.

Chandan Basho, COO and CFO of Astrana Health, Inc., reported a transaction involving the surrender of shares to cover tax withholding obligations upon the vesting of restricted stock.

Astrana Health, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and a proposal to increase equity incentive plan shares.

Astrana Health, Inc. announces its 2025 Annual Meeting and details proposals for stockholder voting, including the election of directors, ratification of the company's accounting firm, and approval of executive compensation and an equity incentive plan.

Astrana Health is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of Ernst & Young LLP, approve executive compensation, and approve an amended equity incentive plan.

Astrana Health, Inc. announces its 2024 Annual Meeting to be held on June 12, 2024, with stockholders voting on the election of directors, ratification of the accounting firm, executive compensation, approval of the 2024 Equity Incentive Plan, and an amendment to the company's Restated Certificate of Incorporation.

Astrana Health's proxy statement details proposals for the 2024 annual meeting, including director elections, auditor ratification, executive compensation, a new equity incentive plan, and officer exculpation.

Allied Physicians of California, a significant shareholder in Astrana Health, Inc., has filed an amendment to its Schedule 13D, detailing a recent pro rata distribution of 699,896 shares of Astrana Health common stock to its own stockholders.

Astrana Health, Inc. has repurchased 300,000 shares of its common stock from Allied Physicians of California for $10.55 million, while Allied Physicians also declared a dividend of nearly 700,000 Astrana shares to its own stockholders.

Vanguard Portfolio Management has reported a beneficial ownership of 5.34% in Astrana Health Inc., holding 2,648,939 shares.

The Vanguard Group reported an 8.45% beneficial ownership in Astrana Health Inc. common stock, alongside an internal realignment affecting future reporting.

The Vanguard Group has reported a 9.68% beneficial ownership stake in Astrana Health Inc., holding 4,833,384 shares of common stock as a passive investment.

BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, reporting a 12.4% beneficial ownership stake in Astrana Health, Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has reported a beneficial ownership of 11.4% of Astrana Health, Inc.'s common stock, totaling 6,433,206 shares, as of December 31, 2024, indicating a passive investment.